A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases

NCT02633397 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

130

Enrollment

OTHER

Sponsor class

Conditions

Sickle Cell Disease

Interventions

DRUG: Riociguat
DRUG: Placebo

Sponsor

Mark Gladwin